Last reviewed · How we verify
Ketamine plus usual care
Ketamine blocks NMDA glutamate receptors in the brain, producing rapid-onset dissociative anesthesia and analgesic effects.
Ketamine plus usual care, marketed by The University of Texas Health Science Center, Houston, is a treatment currently available in the market. A key strength is the protection provided by the key composition patent, which expires in 2028. The primary risk is the lack of detailed revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Ketamine plus usual care |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia, Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ketamine is a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor. This blockade interrupts pain signal transmission and produces dissociative anesthesia. When combined with usual care, ketamine may provide enhanced analgesia and sedation in acute or perioperative settings.
Approved indications
- Anesthesia induction and maintenance (in combination with standard care)
- Acute pain management (in combination with standard care)
Common side effects
- Dissociation
- Increased heart rate
- Increased blood pressure
- Dizziness
- Nausea
Key clinical trials
- Cardiac Index and General Anesthesia Without Opioid. (PHASE2, PHASE3)
- Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression (PHASE2)
- Behavioural Activation Therapy and Esketamine for Resistant Depression (NA)
- Efficacy of Esketamine for Patients With Irritable Bowel Syndrome (NA)
- Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities (PHASE4)
- Ketamine in OCD: Efficacy and Effects on Stress and Cognition (NA)
- Opioid-free Analgesia in Intensive Care Unit (PHASE4)
- Ketamine & Crisis Response Plan for Suicidal Ideation in the ED (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: